CD4 and diabetes mellitus: Importantly, also in a very aggressive variant of this diabetes model, where activated BDC2.5 TCR–Tg CD4+ T cells (1 × 105) were transferred into NOD.SCID recipients, ISO-1 was successful in significantly delaying disease onset (median onset, 13±0.8 vs. 21±2.0 days; Fig 5B).